Injectable Drug Delivery Market Size, Share & Trends by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), Distribution Channel, Patient Care Setting, & Region - Global Forecast to 2029
Report Code: MD 3680 May, 2024, by marketsandmarkets.com
Injectable Drug Delivery Market Size, Share & Trends
The size of global Injectable drug delivery market in terms of revenue was estimated to be worth $754.5 billion in 2024 and is poised to reach $1139.4 billion by 2029, growing at a CAGR of 8.6% from 2024 to 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
Growth of the Injectable drug delivery market is mainly driven by increasing prevalence of Infectious diseases, Increasing technological advancements and increasing funding scenarios for R&D for the Injectable drug delivery market.
Injectable Drug Delivery Market Trends
To know about the assumptions considered for the study, Request for Free Sample Report
Injectable Drug Delivery Market Dynamics
DRIVER: Increased Prevalence of Chronic Diseases
Injectable drug administration is critical for the treatment of a variety of infectious disorders, including bacterial, viral, fungal, and parasitic infections. Many antibiotics, antiviral treatments, antifungal agents, and antiparasitic therapies are supplied intravenously to achieve quick and effective drug concentrations in the bloodstream and target tissues.Injectable drugs are widely used to treat chronic infectious diseases such as tuberculosis (TB) and HIV/AIDS. To successfully target the TB germs and prevent medication resistance, TB treatment frequently combines oral antibiotics with injectable treatments such as rifampin, isoniazid, and streptomycin. Similarly, injectable antiretroviral medications can be used in HIV/AIDS therapy regimens to inhibit viral replication and slow disease progression.
RESTRAINT: Infections associated with needlestick injuries
Needlestick injuries, also known as percutaneous injuries, can transmit a variety of infectious pathogens if the needle or sharp instrument comes into contact with blood or bodily fluids. Other bloodborne infections that can be transmitted through needle injuries include syphilis, malaria, and human T-cell lymphotropic virus (HTLV). These infections can result in a variety of symptoms and problems, depending on the pathogen.
In addition to bloodborne pathogens, needlestick injuries can bring germs into the body, causing localized or systemic illness. Staphylococcus aureus, Streptococcus species, and gram-negative bacteria are among the most common bacterial illnesses associated with needlestick injuries.
OPPORTUNITY: Increase in demand for biosimilars and generic medicine
The need for biosimilars and generic injectable pharmaceuticals allows pharmaceutical companies to diversify their product portfolios in the injectable drug delivery sector. Companies can develop and manufacture a wide range of injectable biosimilars and generic pharmaceuticals for a variety of therapeutic areas, including oncology, autoimmune diseases, diabetes, and infectious diseases, to fulfill the growing demand for affordable and accessible treatments. Biosimilars and generic injectable drugs are less expensive and more affordable than brand-name medications, making them more accessible to individuals, healthcare providers, and healthcare systems. Injectable drug delivery systems are critical in the administration of biosimilars and generic pharmaceuticals, providing safe, effective, and easy delivery options for patients undergoing long-term or chronic therapies.
CHALLENGE: Preference for other modes of drug delivery
The injectable mode of drug delivery offers a large surface area for absorption as a result of which it achieves rapid systemic levels of absorption. However, the use of injectables can lead to needlestick injuries and infections, needle phobia, anxiety, and pain. All these factors limit the market for injectables to a certain extent. Among the various routes of drug delivery, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable.
Inhalation facilitates rapid absorption due to the huge surface area of the respiratory endothelium; bronchodilators and inhaled steroids can be targeted at the lungs with low levels of systemic absorption. The topical route of drug administration is considered better than injections as drugs are applied directly to the skin and it is non-invasive, easy, and there is a high level of patient compliance.
This preference for other routes of drug administration is a major challenge for the injectable drug delivery technology market.
Injectable drug delivery industry Ecosystem
The Formulations segment of the Injectable drug delivery industry is witnessed to have the highest growth during the forecast period.
Injectable formulations serve a wide range of therapeutic needs, including oncology, diabetes, autoimmune illnesses, cardiovascular disease, and infectious diseases. Each therapeutic category may necessitate unique formulations tailored to the drug's properties and the needs of the patient population, adding to the formulation segment's diversity. Continuous improvements in drug delivery technology enable the creation of novel formulations with improved features such as sustained release, targeted distribution, and increased stability. These developments fuel market expansion by increasing the number of injectable formulations available to healthcare practitioners and patients.
By Therapeutic application Infectious diseases segment of the Injectable drug delivery industry holds the largest share for 2023.
Vaccines are critical instruments for preventing infectious illnesses and mitigating their effects on public health. Injectable vaccinations are frequently used in immunization programs against a variety of infectious illnesses, including influenza, measles, polio, hepatitis, and human papillomavirus (HPV). The substantial percentage of injectable vaccinations in therapeutic applications is due to their development, manufacture, and dissemination.
Overall, the high share of infectious diseases in all therapeutic applications within the injectable drug market is due to the global burden of these diseases, the wide range of conditions they cover, the challenges posed by antimicrobial resistance, the prevalence of hospital-acquired infections, the impact of globalization and travel on disease spread, and the importance of vaccines in disease prevention and control.
By Route of Administration Skin/Intradermal accounted for the highest share of the Injectable drug delivery industry during the forecast period.
Compared to other delivery methods like intravenous or intramuscular injections, subcutaneous injections are comparatively easy to perform and don't require specific medical knowledge or equipment. In a variety of clinical settings, such as clinics, hospitals, and home healthcare settings, healthcare personnel can effortlessly provide subcutaneous injections.Drugs can be absorbed into the bloodstream more quickly and consistently in subcutaneous tissue because it has a robust blood supply and a comparatively large surface area. Because of this, subcutaneous injections are appropriate for drugs that need steady-state plasma concentrations because they enable predictable pharmacokinetics and dosage schedules.
North America accounted for the largest share of the Injectable drug delivery industry in 2023.
To know about the assumptions considered for the study, download the pdf brochure
Based on the region, the Injectable drug delivery market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of the Injectable drug delivery market. This is due to an increase in the prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders. North America has one of the world's highest healthcare expenditures per capita. Significant investment in healthcare infrastructure, research, and pharmaceuticals helps to promote the widespread use of injectable drug delivery systems in the region.
Prominent players in the injectable drug delivery market are Becton, Dickinson and Company (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Eli Lilly and Company (U.S.), Baxter International, Inc. (U.S.), Sandoz (Germany), Terumo (Japan), Schott AG (Germany), Gerresheimer (Germany), Ypsomed (Switzerland), and B. Braun Melsungens (Germany).
Scope of the Injectable Drug Delivery Industry:
|
Report Metric |
Details |
|
Market Revenue in 2024 |
$754.5 billion |
|
Projected Revenue by 2029 |
$1139.4 billion |
|
Revenue Rate |
Poised to Grow at a CAGR of 8.6% |
|
Market Driver |
Increased Prevalence of Chronic Diseases |
|
Market Opportunity |
Increase in demand for biosimilars and generic medicine |
The study categorizes the injectable drug delivery market to forecast revenue and analyze trends in each of the following submarkets:
By Devices
- Conventional Injection Devices
-
By material
- Glass
- Plastic
-
By Product
- Fillable Syringes
- Prefilled Syringes
-
By Usability
- Reusable Injection Devices
- Disposable Injection Devices
- Self-injection devices
- Needle-free Injectors
-
By Product
- Fillable Needle-free Injectors
- Prefilled Needle-free Injectors
-
By Technology
- Jet-based Needle-free Injectors
- Spring-based Needle-free Injectors
-
Laser-powered needle free-injectors
- Vibration-based Needle-free Injectors
-
By Usability
- Reusable needle-free Injectors
- Disposable needle-free Injectors
- Autoinjectors
-
By Product
- Fillable Autoinjectors
- Prefilled Autoinjectors
-
By Technology
- Automated Autoinjectors
- Manual Autoinjectors
-
By Design
- Standardized Autoinjectors
- Customized Autoinjectors
-
By Usability
- Reusable Autoinjectors
- Disposable Autoinjectors
- Pen Injectors
-
By Product
- Single-chambered Pen Injectors
- Dual-chambered Pen Injectors
-
By Design
- Standard Pen Injectors
- Customized Pen Injectors
-
By Usability
- Reusable Pen Injectors
- Disposable Pen Injectors
- Wearable Injectors
- Other Devices
- FORMULATIONS
-
CONVENTIONAL DRUG DELIVERY FORMULATIONS
- Solutions
- Reconstituted/Lyophilized formulations
- Suspensions
- Emulsions
-
NOVEL DRUG DELIVERY FORMULATIONS
- Colloidal dispersions
- Niosomes
- Liposomes
- Polymeric/mixed micelles
- Nanoparticles
- Solid-lipid nanoparticles
- Nanosuspensions
- Nanoemulsions
-
MICROPARTICLES
- Microspheres
- Microcapsules
- LONG-ACTING INJECTION FORMULATIONS
By Formulation Packaging
- Introduction
- Amp0ules
- Vials
- Cartridges
- Bottles
By Therapeutic Application
- Introduction
-
Autoimmune diseases
- Rheumatoid arthritis
- Multiple Sclerosis (MS)
- Crohn’s Disease
- Psoriasis
- Other Autoimmune Diseases
-
HORMONAL DISORDERS
- Diabetes
- Anemia
- Reproductive health disease
- Antithrombotic/thrombolytic therapy
- Osteoporosis
- growth hormone deficiency(ghd)
- Orphan diseases
- Cancer
- Infectious diseases
-
Other therapeutic applications
- Pain management
- Allergies
- Aesthetic treatment
- Hepatitis c
- Hemophilia
By Usage Pattern
- Introduction
- Curative care
- Immunization
- Others
By Site of Administration
- Introduction
- Skin(Intradermal and subcutaneous)
- Circulatory/Musculoskeletal system (Intravenous, Intracardiac, Intramuscular and Intraperitoneal)
- Organs (Intravitreal and Intra-articular)
- Central Nervous system ( Intracerebral and intrathecal)
By Distribution Channel
- Introduction
- Hospitals
- Retail Pharmacy stores
By Patient Care Setting
- Introduction
- Hospitals and Clinics
- Home care settings
- Other facilities of Use
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- Italy
- Spain
- France
- RoE
-
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- RoAPAC
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
-
Middle East and Africa
- GCC Countries
- Rest of Middle East and Africa
Recent Developments
- In Sep 2022 BD launched BD EffivaxTM Glass prefillable syringes. This syringe will help in growing demand for vaccines manufacturing.
- In Oct 2022 GSK received its product approval for BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed; Tdap) for immunization during the third trimester of pregnancy to help prevent pertussis (whooping cough) in infants younger than two months old.)
- In Nov 2023 Eli and Lilly received FDA approval for Zepbound injection which is the first and only obesity medication.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global Injectable drug delivery market?
The global Injectable drug delivery market boasts a total revenue value of $1139.4 billion by 2029.
What is the estimated growth rate (CAGR) of the global Injectable drug delivery market?
The global Injectable drug delivery market has an estimated compound annual growth rate (CAGR) of 8.6% and a revenue size in the region of $754.5 billion in 2024. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 51)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
1.4.2 REGIONAL SEGMENTATION
FIGURE 1 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 57)
2.1 RESEARCH DATA
FIGURE 2 INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 6 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
FIGURE 7 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.3 APPROACH 3: TOP-DOWN APPROACH
FIGURE 8 TOP-DOWN APPROACH
2.2.4 APPROACH 2: BOTTOM-UP APPROACH: SUPPLY-SIDE ANALYSIS
FIGURE 9 BOTTOM-UP APPROACH
2.2.5 APPROACH 4: PRIMARY INTERVIEWS
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ASSESSMENT
2.5 STUDY ASSUMPTIONS
TABLE 1 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 71)
FIGURE 11 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
FIGURE 12 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2024 VS. 2029 (USD BILLION)
FIGURE 13 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2024 VS. 2029 (USD BILLION)
FIGURE 14 GEOGRAPHIC SNAPSHOT OF INJECTABLE DRUG DELIVERY MARKET
4 PREMIUM INSIGHTS (Page No. - 75)
4.1 INJECTABLE DRUG DELIVERY MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
4.2 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE AND COUNTRY (2023)
FIGURE 16 FORMULATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
FIGURE 17 SELF-INJECTION DEVICES SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 79)
5.1 MARKET DYNAMICS
FIGURE 19 INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 DRIVERS
5.1.1.1 Rising prevalence of chronic diseases
5.1.1.2 Growing demand for self-injection devices
5.1.1.3 Growth in biologics market
TABLE 3 INDICATIVE LIST OF BIOLOGICS APPROVED BY US FDA (2020)
5.1.1.4 Technological advancements in injectable drug delivery products
5.1.2 RESTRAINTS
5.1.2.1 Infections associated with needlestick injuries
5.1.2.2 Higher cost of development compared to conventional injections
5.1.3 OPPORTUNITIES
5.1.3.1 Increasing demand for biosimilars and generic injectables
5.1.3.1.1 Biosimilars
5.1.3.1.2 Generic injectables
5.1.3.2 Contraceptive injectables
5.1.4 CHALLENGES
5.1.4.1 Alternative methods of drug delivery
5.2 VALUE CHAIN ANALYSIS
5.2.1 RESEARCH & DEVELOPMENT
5.2.2 PROCUREMENT & PRODUCT DEVELOPMENT
5.2.3 MARKETING, SALES & DISTRIBUTION, AND POST-SALES SERVICES
FIGURE 20 INJECTABLE DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
5.3 SUPPLY CHAIN ANALYSIS
5.3.1 PROMINENT COMPANIES
5.3.2 SMALL & MEDIUM-SIZED COMPANIES
5.3.3 END USERS
FIGURE 21 INJECTABLE DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS
5.4 TARIFF AND REGULATORY LANDSCAPE
5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4 REGULATORY SCENARIO, BY COUNTRY
5.5 TARIFF AND REGULATORY ANALYSIS
5.5.1 NORTH AMERICA
5.5.1.1 US
5.5.1.2 Canada
5.5.2 EUROPE
5.5.3 ASIA PACIFIC
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.4 LATIN AMERICA
5.5.5 MIDDLE EAST
5.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 ECOSYSTEM ANALYSIS
FIGURE 22 INJECTABLE DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.3 ADJACENT TECHNOLOGIES
5.9 PATENT ANALYSIS
FIGURE 23 PATENT ANALYSIS FOR INJECTABLE DRUG DELIVERY MARKET (JANUARY 2014–DECEMBER 2023)
5.10 KEY CONFERENCES AND EVENTS, 2023–2024
TABLE 9 INJECTABLE DRUG DELIVERY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023–2024
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
5.12 PORTER’S FIVE FORCES ANALYSIS
FIGURE 25 INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 10 INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 26 KEY STAKEHOLDERS IN BUYING PROCESS
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%)
5.14 REIMBURSEMENT SCENARIO
TABLE 12 REIMBURSEMENT CODES FOR VARIOUS PROCEDURES
5.15 UNMET NEEDS IN INJECTABLE DRUG DELIVERY MARKET
5.16 INVESTMENT SCENARIO
FIGURE 27 NUMBER OF INVESTOR DEALS IN INJECTABLE DRUG DELIVERY MARKET, BY KEY PLAYER, 2019–2022
FIGURE 28 VALUE OF INVESTOR DEALS IN INJECTABLE DRUG DELIVERY MARKET, BY KEY PLAYER, 2019–2022 (USD MILLION)
6 INJECTABLE DRUG DELIVERY MARKET, BY TYPE (Page No. - 106)
6.1 INTRODUCTION
TABLE 13 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
6.2 DEVICES
TABLE 14 INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 15 INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY REGION, 2021–2029 (USD BILLION)
6.2.1 CONVENTIONAL INJECTION DEVICES
6.2.1.1 Rising incidence of chronic diseases and low cost of manufacturing to drive market
TABLE 16 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.1.2 By material
TABLE 17 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2021–2029 (USD BILLION)
6.2.1.2.1 Glass
TABLE 18 CONVENTIONAL GLASS INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.1.2.2 Plastic
TABLE 19 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.1.3 By product
TABLE 20 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2021–2029 (USD BILLION)
6.2.1.3.1 Fillable syringes
TABLE 21 FILLABLE SYRINGES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.1.3.2 Prefilled syringes
TABLE 22 PREFILLED SYRINGES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.1.4 By usability
TABLE 23 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2021–2029 (USD BILLION)
6.2.1.4.1 Reusable injection devices
TABLE 24 REUSABLE INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.1.4.2 Disposable injection devices
TABLE 25 DISPOSABLE INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2 SELF-INJECTION DEVICES
TABLE 26 SELF-INJECTION DEVICES MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 27 SELF-INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1 Needle-free injectors
6.2.2.1.1 Instant and painless administration to boost demand
TABLE 28 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1.2 By product
TABLE 29 NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2021–2029 (USD BILLION)
6.2.2.1.2.1 Fillable needle-free injectors
TABLE 30 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1.2.2 Prefilled needle-free injectors
TABLE 31 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1.3 By technology
TABLE 32 NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD BILLION)
6.2.2.1.3.1 Jet-based needle-free injectors
TABLE 33 JET-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1.3.2 Spring-based needle-free injectors
TABLE 34 SPRING-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1.3.3 Laser-based needle-free injectors
TABLE 35 LASER-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1.3.4 Vibration-based needle-free injectors
TABLE 36 VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1.4 By usability
TABLE 37 NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2021–2029 (USD BILLION)
6.2.2.1.4.1 Reusable needle-free injectors
TABLE 38 REUSABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.1.4.2 Disposable needle-free injectors
TABLE 39 DISPOSABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2 Autoinjectors
6.2.2.2.1 Automated dose delivery to enhance patient care
TABLE 40 AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2.2 By product
TABLE 41 AUTOINJECTORS MARKET, BY PRODUCT, 2021–2029 (USD BILLION)
6.2.2.2.2.1 Fillable autoinjectors
TABLE 42 FILLABLE AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2.2.2 Prefilled autoinjectors
TABLE 43 PREFILLED AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2.3 By technology
TABLE 44 AUTOINJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD BILLION)
6.2.2.2.3.1 Automated autoinjectors
TABLE 45 AUTOMATED AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2.3.2 Manual autoinjectors
TABLE 46 MANUAL AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2.4 By design
TABLE 47 AUTOINJECTORS MARKET, BY DESIGN, 2021–2029 (USD BILLION)
6.2.2.2.4.1 Standardized autoinjectors
TABLE 48 STANDARDIZED AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2.4.2 Customized autoinjectors
TABLE 49 CUSTOMIZED AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2.5 By usability
TABLE 50 AUTOINJECTORS MARKET, BY USABILITY, 2021–2029 (USD BILLION)
6.2.2.2.5.1 Reusable autoinjectors
TABLE 51 REUSABLE AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.2.5.2 Disposable autoinjectors
TABLE 52 DISPOSABLE AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.3 Pen injectors
6.2.2.3.1 Multi-dose devices that can administer dosage subcutaneously
TABLE 53 PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
TABLE 54 TABLE COMMERCIALLY AVAILABLE PEN INJECTORS
6.2.2.3.2 By product
TABLE 55 PEN INJECTORS MARKET, BY PRODUCT, 2021–2029 (USD BILLION)
6.2.2.3.2.1 Single-chambered pen injectors
TABLE 56 SINGLE-CHAMBERED PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.3.2.2 Dual-chambered pen injectors
TABLE 57 DUAL-CHAMBERED PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.3.3 By design
TABLE 58 PEN INJECTORS MARKET, BY DESIGN, 2021–2029 (USD BILLION)
6.2.2.3.3.1 Standard pen injectors
TABLE 59 STANDARD PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.3.3.2 Customized pen injectors
TABLE 60 CUSTOMIZED PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.3.4 By usability
TABLE 61 PEN INJECTORS MARKET, BY USABILITY, 2021–2029 (USD BILLION)
6.2.2.3.4.1 Reusable pen injectors
TABLE 62 REUSABLE PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.3.4.2 Disposable pen injectors
TABLE 63 DISPOSABLE PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.4 Wearable injectors
6.2.2.4.1 High efficacy and enhanced safety to drive market
TABLE 64 WEARABLE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.2.2.5 Other devices
TABLE 65 INJECTABLE DRUG DELIVERY MARKET FOR OTHER DEVICES, BY REGION, 2021–2029 (USD BILLION)
6.3 FORMULATIONS
TABLE 66 INJECTABLE DRUG DELIVERY MARKET FOR FORMULATIONS, BY TYPE, 2021–2029 (USD BILLION)
TABLE 67 INJECTABLE DRUG DELIVERY MARKET FOR FORMULATIONS, BY REGION, 2021–2029 (USD BILLION)
6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
TABLE 68 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 69 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.1.1 Solutions
6.3.1.1.1 High stability and sterility benefits to fuel uptake
TABLE 70 SOLUTIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.1.2 Reconstituted/lyophilized formulations
6.3.1.2.1 Suitable for parenteral administration
TABLE 71 RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.1.3 Suspensions
6.3.1.3.1 administered using conventional syringes or cartridges
TABLE 72 SUSPENSIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.1.4 Emulsions
6.3.1.4.1 Thermodynamic dispersions delivered intravenously
TABLE 73 EMULSIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2 NOVEL DRUG DELIVERY FORMULATIONS
TABLE 74 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 75 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.1 Colloidal dispersions
TABLE 76 COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 77 COLLOIDAL DISPERSIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.1.1 Niosomes
6.3.2.1.1.1 Features include versatility and flexibility
TABLE 78 NIOSOMES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.1.2 Liposomes
6.3.2.1.2.1 Non-toxic and biocompatible with several indications
TABLE 79 LIPOSOMES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.1.3 Polymeric/mixed micelles
6.3.2.1.3.1 Ability to deliver hydrophobic drugs with slower dissolution rates
TABLE 80 POLYMERIC/MIXED MICELLES MARKET, BY REGION, 2021–2029 USD BILLION)
6.3.2.1.4 Nanoparticles
TABLE 81 NANOPARTICLES MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 82 NANOPARTICLES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.1.4.1 Solid-lipid nanoparticles
6.3.2.1.4.1.1 High uptake in parenteral nutrition
TABLE 83 SOLID-LIPID NANOPARTICLES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.1.4.2 Nanosuspensions
6.3.2.1.4.2.1 Ability to enhance solubility and permeability of drug formulations
TABLE 84 NANOSUSPENSIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.1.4.3 Nanoemulsions
6.3.2.1.4.3.1 Utilized in antibiotic therapy and vaccine delivery
TABLE 85 NANOEMULSIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.2 Microparticles
TABLE 86 MICROPARTICLES MARKET, BY TYPE, 2021–2029 (USD BILLION)
6.3.2.2.1 Microspheres
6.3.2.2.1.1 Particulate carrier systems with high bioavailability
TABLE 87 MICROSPHERES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.2.2.2 Microcapsules
6.3.2.2.2.1 Polymeric excipients with biodegradable features
TABLE 88 MICROCAPSULES MARKET, BY REGION, 2021–2029 (USD BILLION)
6.3.3 LONG-ACTING INJECTABLE FORMULATIONS
6.3.3.1 Advantages include cost efficiency and low side effects
TABLE 89 LONG-ACTING INJECTABLE FORMULATIONS MARKET, BY REGION, 2021–2029 (USD BILLION)
7 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION (Page No. - 153)
7.1 INTRODUCTION
TABLE 90 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
7.2 AUTOIMMUNE DISEASES
TABLE 91 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 92 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2029 (USD BILLION)
7.2.1 RHEUMATOID ARTHRITIS
7.2.1.1 Increased focus on early-stage diagnosis and treatment to propel segment growth
TABLE 93 INJECTABLE DRUG DELIVERY MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2029 (USD BILLION)
7.2.2 MULTIPLE SCLEROSIS
7.2.2.1 Increasing target patient pool to drive market
TABLE 94 INJECTABLE DRUG DELIVERY MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2029 (USD BILLION)
7.2.3 CROHN’S DISEASE
7.2.3.1 Increasing use of liposomes to aid segment growth
TABLE 95 INJECTABLE DRUG DELIVERY MARKET FOR CROHN’S DISEASE, BY REGION, 2021–2029 (USD BILLION)
7.2.4 PSORIASIS
7.2.4.1 Lifestyle changes and high disease prevalence to support market growth
TABLE 96 INJECTABLE DRUG DELIVERY MARKET FOR PSORIASIS, BY REGION, 2021–2029 (USD BILLION)
7.2.5 OTHER AUTOIMMUNE DISEASES
TABLE 97 INJECTABLE DRUG DELIVERY MARKET FOR OTHER AUTOIMMUNE DISEASES, BY REGION, 2021–2029 (USD BILLION)
7.3 HORMONAL DISORDERS
TABLE 98 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2021–2029 (USD BILLION)
7.3.1 DIABETES
7.3.1.1 Growing preference for self-injection devices over traditional syringes to augment market growth
TABLE 99 INJECTABLE DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2021–2029 (USD BILLION)
7.3.2 ANEMIA
7.3.2.1 Increasing occurrence of nutritional deficiency to drive market
TABLE 100 INJECTABLE DRUG DELIVERY MARKET FOR ANEMIA, BY REGION, 2021–2029 (USD BILLION)
7.3.3 REPRODUCTIVE HEALTH DISEASES
7.3.3.1 Lack of healthcare facilities and hygiene practices to aid market growth
TABLE 101 INJECTABLE DRUG DELIVERY MARKET FOR REPRODUCTIVE HEALTH DISEASES, BY REGION, 2021–2029 (USD BILLION)
7.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
7.3.4.1 High efficacy and safety of heparin for antithrombotic therapy to drive segment
TABLE 102 INJECTABLE DRUG DELIVERY MARKET FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY REGION, 2021–2029 (USD BILLION)
7.3.5 OSTEOPOROSIS
7.3.5.1 Increasing number of women with calcium and vitamin D deficiency to boost segment growth
TABLE 103 INJECTABLE DRUG DELIVERY MARKET FOR OSTEOPOROSIS, BY REGION, 2021–2029 (USD BILLION)
7.3.6 GROWTH HORMONE DEFICIENCY
7.3.6.1 Increased need for daily injections of recombinant human growth hormones to fuel market growth
TABLE 104 INJECTABLE DRUG DELIVERY MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2021–2029 (USD BILLION)
7.4 ORPHAN DISEASES
7.4.1 INCREASING NUMBER OF LEGAL AND FINANCIAL INITIATIVES BY GOVERNMENT TO AUGMENT MARKET GROWTH
TABLE 105 INJECTABLE DRUG DELIVERY MARKET FOR ORPHAN DISEASES, BY REGION, 2021–2029 (USD BILLION)
7.5 CANCER
7.5.1 RISING PREVALENCE OF CANCER AND GROWING AVAILABILITY OF THERAPEUTICS TO DRIVE MARKET
TABLE 106 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2021–2029 (USD BILLION)
7.6 INFECTIOUS DISEASES
7.6.1 ENVIRONMENTAL CHANGES AND INCREASED MICROBIAL ADAPTATION TO BOOST MARKET GROWTH
TABLE 107 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2029 (USD BILLION)
7.7 OTHER THERAPEUTIC APPLICATIONS
TABLE 108 INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2029 (USD BILLION)
7.7.1 PAIN MANAGEMENT
7.7.1.1 Increasing number of new drugs for chronic pain management to aid market growth
TABLE 109 INJECTABLE DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY REGION, 2021–2029 (USD BILLION)
7.7.2 ALLERGIES
7.7.2.1 Increasing prevalence of asthma and eczema to drive market
TABLE 110 INJECTABLE DRUG DELIVERY MARKET FOR ALLERGIES, BY REGION, 2021–2029 (USD BILLION)
7.7.3 AESTHETIC TREATMENTS
7.7.3.1 Growing popularity of aesthetic procedures to propel segment growth
TABLE 111 INJECTABLE DRUG DELIVERY MARKET FOR AESTHETIC TREATMENTS, BY REGION, 2021–2029 (USD MILLION)
7.7.4 HEPATITIS C
7.7.4.1 Reuse of INJECTABLEs and inadequate equipment sterilization to drive market
TABLE 112 INJECTABLE DRUG DELIVERY MARKET FOR HEPATITIS C, BY REGION, 2021–2029 (USD BILLION)
7.7.5 HEMOPHILIA
7.7.5.1 Increasing need for preventive treatment plans to propel segment growth
TABLE 113 INJECTABLE DRUG DELIVERY MARKET FOR HEMOPHILIA, BY REGION, 2021–2029 (USD MILLION)
8 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING (Page No. - 173)
8.1 INTRODUCTION
TABLE 114 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
8.2 AMPOULES
8.2.1 HELPS MAINTAIN STABILITY OF DRUGS, THEREBY ENHANCING EFFICACY
TABLE 115 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY REGION, 2021–2029 (USD BILLION)
8.3 VIALS
8.3.1 ABILITY TO STORE DRUG FORMULATIONS FOR EXTENSIVE PERIODS
TABLE 116 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY REGION, 2021–2029 (USD BILLION)
8.4 CARTRIDGES
8.4.1 OFFERS HIGHER DOSE ACCURACY AND PATIENT CONVENIENCE
TABLE 117 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY REGION, 2021–2029 (USD BILLION)
8.5 BOTTLES
8.5.1 STORAGE OF SOLUTIONS AND EMULSIONS
TABLE 118 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY REGION, 2021–2029 (USD BILLION)
9 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN (Page No. - 178)
9.1 INTRODUCTION
TABLE 119 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
9.2 CURATIVE CARE
9.2.1 ADMINISTRATION OF THERAPEUTIC MEDICATIONS FOR EARLY DISEASE DETECTION TO PROPEL MARKET
TABLE 120 INJECTABLE DRUG DELIVERY MARKET FOR CURATIVE CARE, BY REGION, 2021–2029 (USD BILLION)
9.3 IMMUNIZATION
9.3.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND
TABLE 121 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNIZATION, BY REGION, 2021–2029 (USD BILLION)
9.4 OTHER USAGE PATTERNS
TABLE 122 INJECTABLE DRUG DELIVERY MARKET FOR OTHER USAGE PATTERNS, BY REGION, 2021–2029 (USD BILLION)
10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION (Page No. - 183)
10.1 INTRODUCTION
TABLE 123 TABLE 1: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
10.2 SKIN-BASED ADMINISTRATION
10.2.1 RAPID & EFFECTIVE METHOD WITH LOW PAIN TO DRIVE MARKET
TABLE 124 INJECTABLE DRUG DELIVERY MARKET FOR SKIN-BASED ADMINISTRATION, BY REGION, 2021–2029 (USD BILLION)
10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT MARKET GROWTH
TABLE 125 INJECTABLE DRUG DELIVERY MARKET FOR CIRCULATORY/MUSCULOSKELETAL-BASED ADMINISTRATION, BY REGION, 2021–2029 (USD BILLION)
10.4 ORGAN-BASED ADMINISTRATION
10.4.1 UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST DEMAND
TABLE 126 INJECTABLE DRUG DELIVERY MARKET BY ORGAN-BASED ADMINISTRATION, BY REGION, 2021–2029 (USD BILLION)
10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
10.5.1 ADOPTION OF MIS TECHNIQUES TO DRIVE MARKET
TABLE 127 INJECTABLE DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION, BY REGION, 2021–2029 (USD BILLION)
11 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL (Page No. - 188)
11.1 INTRODUCTION
TABLE 128 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
11.2 HOSPITALS
11.2.1 HIGH UPTAKE OF ADVANCED DRUG FORMULATIONS TO DRIVE MARKET
TABLE 129 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2021–2029 (USD BILLION)
11.3 RETAIL PHARMACY STORES
11.3.1 SALE OF OTC AND PRESCRIPTION DRUGS TO SUPPORT MARKET GROWTH
TABLE 130 INJECTABLE DRUG DELIVERY MARKET FOR RETAIL PHARMACY STORES, BY REGION, 2021–2029 (USD BILLION)
12 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS (Page No. - 191)
12.1 INTRODUCTION
TABLE 131 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
12.2 HOSPITALS AND CLINICS
12.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
TABLE 132 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2029 (USD BILLION)
12.3 HOME CARE SETTINGS
12.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET
TABLE 133 INJECTABLE DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2029 (USD BILLION)
12.4 OTHER PATIENT CARE SETTINGS
TABLE 134 INJECTABLE DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE, BY REGION, 2021–2029 (USD BILLION)
13 INJECTABLE DRUG DELIVERY MARKET, BY REGION (Page No. - 195)
13.1 INTRODUCTION
13.1.1 NORTH AMERICA: RECESSION IMPACT
TABLE 135 INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2021–2029 (USD BILLION)
13.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
TABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021–2029 (USD BILLION)
TABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 141 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 142 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 143 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 144 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.2.1 US
13.2.1.1 US to command largest share in North American INJECTABLE drug delivery market during forecast period
TABLE 145 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 146 US: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 147 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 148 US: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 149 US: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 150 US: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 151 US: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 152 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 153 US: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.2.2 CANADA
13.2.2.1 Increasing government support and rising incidence of chronic diseases to drive market
TABLE 154 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 155 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 156 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 157 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 158 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 159 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 160 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 161 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 162 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.3 EUROPE
13.3.1 EUROPE: RECESSION IMPACT
TABLE 163 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021–2029 (USD BILLION)
TABLE 164 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 165 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 166 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 167 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 168 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 169 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 170 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 171 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 172 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.3.2 GERMANY
13.3.2.1 High healthcare expenditure and increased focus on pharmaceutical R&D to drive market
TABLE 173 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 174 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 175 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 176 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 177 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 178 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 179 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 180 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 181 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.3.3 FRANCE
13.3.3.1 Increasing geriatric population and rising incidence of autoimmune diseases to spur market growth
TABLE 182 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 183 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 184 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 185 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 186 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 187 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 188 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 189 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 190 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.3.4 UK
13.3.4.1 Growing adoption of generics and increasing collaborations between government and private bodies to aid market growth
TABLE 191 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 192 UK: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 193 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 194 UK: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 195 UK: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 196 UK: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 197 UK: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 198 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 199 UK: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.3.5 ITALY
13.3.5.1 Low healthcare expenditure and economic downturn to limit market growth
TABLE 200 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 201 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD MILLION)
TABLE 202 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 203 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 204 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 205 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 206 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 207 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 208 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.3.6 SPAIN
13.3.6.1 Increasing number of mergers and acquisitions to support market growth
TABLE 209 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 210 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD MILLION)
TABLE 211 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 212 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 213 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 214 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 215 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 216 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 217 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.3.7 REST OF EUROPE
TABLE 218 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 219 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 220 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 221 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 222 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 223 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 224 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 225 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 226 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.4 ASIA PACIFIC
13.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 30 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
TABLE 227 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021–2029 (USD BILLION)
TABLE 228 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 229 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 230 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 231 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 232 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 233 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 234 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 235 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 236 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.4.2 CHINA
13.4.2.1 Rising prevalence of chronic diseases to augment market growth
TABLE 237 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 238 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 239 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 240 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 241 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 242 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 243 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 244 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 245 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.4.3 JAPAN
13.4.3.1 Growing geriatric population and rising demand for self-injections to drive market
TABLE 246 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 247 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 248 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 249 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 250 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 251 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 252 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 253 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 254 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.4.4 INDIA
13.4.4.1 High incidence of cancer and increased adoption of biosimilars to fuel market growth
TABLE 255 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 256 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 257 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 258 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 259 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 260 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 261 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
13.4.5 AUSTRALIA
13.4.5.1 Increase in R&D funding and favorable taxation policies to fuel market growth
TABLE 262 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 263 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 264 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 265 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 266 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 267 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 268 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 269 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 270 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.4.6 SOUTH KOREA
13.4.6.1 Increasing focus on aesthetic INJECTABLE treatments to drive market
TABLE 271 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 272 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 273 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 274 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 275 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 276 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 277 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 278 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 279 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.4.7 REST OF ASIA PACIFIC
TABLE 280 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 281 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 282 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 283 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 284 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 285 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 286 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 287 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 288 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.5 LATIN AMERICA
13.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 289 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021–2029 (USD BILLION)
TABLE 290 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 291 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 292 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 293 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 294 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 295 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 296 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 297 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 298 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.5.2 BRAZIL
13.5.2.1 Increasing obesity and rising incidence of chronic diseases to augment market growth
TABLE 299 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 300 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 301 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 302 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 303 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 304 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 305 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 306 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 307 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.5.3 MEXICO
13.5.3.1 Growing medical tourism and increasing focus of government on healthcare to propel market
TABLE 308 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 309 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 310 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 311 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 312 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 313 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 314 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 315 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 316 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.5.4 REST OF LATIN AMERICA
TABLE 317 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 318 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 319 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 320 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 321 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 322 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 323 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 324 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 325 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.6 MIDDLE EAST & AFRICA
13.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 326 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2021–2029 (USD BILLION)
TABLE 327 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 328 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 329 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 330 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 331 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 332 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 333 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 334 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 335 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.6.2 GCC COUNTRIES
13.6.2.1 Increasing healthcare expenditure to drive market
TABLE 336 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 337 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 338 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 339 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 340 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 341 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 342 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 343 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 344 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
13.6.3 REST OF MIDDLE EAST & AFRICA
TABLE 345 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION)
TABLE 346 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION)
TABLE 347 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION)
TABLE 348 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION)
TABLE 349 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION)
TABLE 350 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION)
TABLE 351 REST OF MIDDLE EAST AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION)
TABLE 352 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION)
TABLE 353 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION)
14 COMPETITIVE LANDSCAPE (Page No. - 302)
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 31 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
14.3 REVENUE ANALYSIS
FIGURE 32 SEGMENTAL REVENUE ANALYSIS FOR KEY PLAYERS, 2020−2023 (USD MILLION)
14.4 MARKET SHARE ANALYSIS
FIGURE 33 INJECTABLE DRUG DELIVERY MARKET SHARE ANALYSIS, BY KEY PLAYER (2023)
TABLE 354 INJECTABLE DRUG DELIVERY MARKET: DEGREE OF COMPETITION
14.5 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2023
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
FIGURE 34 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
14.5.5 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
TABLE 355 FORMULATION PACKAGING: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
TABLE 356 THERAPEUTIC APPLICATIONS: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
TABLE 357 USAGE PATTERN: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
TABLE 358 SITE OF ADMINISTRATION: INJECTABLE DRUG DELIVERY FORMULATIONS MANUFACTURERS (2023)
TABLE 359 REGION FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATIONS MANUFACTURERS (2023)
FIGURE 35 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
14.6 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
14.6.1 STARS
14.6.2 EMERGING LEADERS
14.6.3 PERVASIVE PLAYERS
14.6.4 PARTICIPANTS
FIGURE 36 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
14.6.5 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
TABLE 360 FORMULATION PACKAGING: INJECTABLE DRUG DELIVERY DEVICES MANUFACTURERS (2023)
TABLE 361 THERAPEUTIC APPLICATIONS: INJECTABLE DRUG DELIVERY DEVICES MANUFACTURERS (2023)
TABLE 362 USAGE PATTERN: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
TABLE 363 SITE OF ADMINISTRATION: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
TABLE 364 REGION FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
FIGURE 37 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
14.6.6 COMPANY BENCHMARKING
TABLE 365 INJECTABLE DRUG DELIVERY MANUFACTURERS MARKET
14.7 COMPANY VALUATION AND FINANCIAL METRICS
FIGURE 38 EV/EBITDA OF KEY VENDORS
FIGURE 39 5-YEAR STOCK BETA OF KEY VENDORS
14.8 PRODUCT/BRAND COMPARISON
FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY TYPE (2023)
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 366 INJECTABLE DRUG DELIVERY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
14.9.2 DEALS
TABLE 367 INJECTABLE DRUG DELIVERY MARKET: DEALS, JANUARY 2021– MARCH 2024
15 COMPANY PROFILES (Page No. - 322)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
15.1 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
15.1.1 BECTON, DICKINSON AND COMPANY
TABLE 368 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 369 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
TABLE 370 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS
TABLE 371 BECTON, DICKINSON AND COMPANY: DEALS
TABLE 372 BECTON, DICKINSON AND COMPANY: EXPANSIONS
15.1.2 PFIZER, INC.
TABLE 373 PFIZER, INC.: COMPANY OVERVIEW
FIGURE 42 PFIZER, INC.: COMPANY SNAPSHOT (2023)
TABLE 374 PFIZER, INC.: PRODUCTS OFFERED
TABLE 375 PFIZER, INC.: PRODUCT APPROVALS
TABLE 376 PFIZER, INC.: DEALS
15.1.3 JOHNSON & JOHNSON SERVICES, INC.
TABLE 377 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
FIGURE 43 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022)
TABLE 378 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
TABLE 379 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 380 JOHNSON & JOHNSON SERVICES, INC.: DEALS
15.1.4 SANDOZ GROUP AG
TABLE 381 SANDOZ GROUP AG: COMPANY OVERVIEW
FIGURE 44 SANDOZ GROUP AG: COMPANY SNAPSHOT (2023)
TABLE 382 SANDOZ GROUP AG: PRODUCTS OFFERED
TABLE 383 SANDOZ GROUP AG: PRODUCT LAUNCHES & APPROVALS
TABLE 384 SANDOZ GROUP AG: DEALS
15.1.5 MERCK& CO., INC.
TABLE 385 MERCK & CO. INC.: COMPANY OVERVIEW
FIGURE 45 MERCK & CO., INC.: COMPANY SNAPSHOT (2022)
TABLE 386 MERCK & CO., INC.: PRODUCTS OFFERED
TABLE 387 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 388 MERCK & CO., INC.: DEALS
15.1.6 GLAXOSMITHKLINE PLC
TABLE 389 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
FIGURE 46 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)
TABLE 390 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
TABLE 391 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS
TABLE 392 GLAXOSMITHKLINE PLC: DEALS
TABLE 393 GLAXOSMITHKLINE PLC: EXPANSIONS
15.1.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 394 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
FIGURE 47 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
TABLE 395 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 396 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES & APPROVALS
TABLE 397 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS
15.1.8 ELI LILLY AND COMPANY
TABLE 398 ELI LILLY AND COMPANY: COMPANY OVERVIEW
FIGURE 48 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
TABLE 399 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 400 ELI LILLY AND COMPANY: PRODUCTS LAUNCHES & APPROVALS
TABLE 401 ELI LILLY AND COMPANY: DEALS
TABLE 402 ELI LILLY AND COMPANY: EXPANSIONS
15.1.9 SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 403 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
TABLE 404 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 405 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS
TABLE 406 SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS
15.1.10 BAXTER INTERNATIONAL, INC.
TABLE 407 BAXTER INTERNATIONAL, INC.: COMPANY OVERVIEW
FIGURE 49 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
TABLE 408 BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED
TABLE 409 BAXTER INTERNATIONAL, INC.: PRODUCT APPROVALS
15.1.11 GERRESHEIMER AG
TABLE 410 GERRESHEIMER AG: COMPANY OVERVIEW
FIGURE 50 GERRESHEIMER AG: COMPANY SNAPSHOT (2022)
TABLE 411 GERRESHEIMER AG: PRODUCTS OFFERED
TABLE 412 GERRESHEIMER AG: PRODUCT LAUNCHES
TABLE 413 GERRESHMEIMER AG: DEALS
15.1.12 SCHOTT PHARMA
TABLE 414 SCHOTT PHARMA: COMPANY OVERVIEW
FIGURE 51 SCHOTT AG: COMPANY SNAPSHOT (2022)
TABLE 415 SCHOTT PHARMA: PRODUCTS OFFERED
TABLE 416 EXPANSIONS
15.2 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
15.2.1 TERUMO CORPORATION
TABLE 417 TERUMO CORPORATION: COMPANY OVERVIEW
FIGURE 52 TERUMO CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 418 TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 419 PRODUCT LAUNCHES & APPROVALS
15.2.2 ANTARES PHARMA, INC.
TABLE 420 ANTARES PHARMA, INC.: COMPANY OVERVIEW
15.2.3 B. BRAUN MELSUNGEN AG
TABLE 421 B. BRAUN MELSUNGEN AG: COMPANY OVERVIEW
15.2.4 SMITHS MEDICAL
TABLE 422 SMITHS MEDICAL: COMPANY OVERVIEW
15.2.5 FRESENIUS KABI AG
TABLE 423 FRESENIUS KABI AG: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
16 APPENDIX (Page No. - 396)
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 RELATED REPORTS
16.4 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the Injectable drug delivery market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for the study of apheresis Market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after obtaining information regarding the apheresis market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief X Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, product development/innovation teams, and related key executives from manufacturers; distributors operating in the Injectable drug delivery market.; and key opinion leaders.
Primary interviews were conducted to gather insights such as market statistics, data on revenue collected from the products and services, market breakdowns, market size estimations, market forecasting, and data triangulation. Primary research also helped in understanding the various trends related to technology, application, vertical, and region. Stakeholders from the demand side customers/end users who are using infection control products were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.
The following is a breakdown of the primary respondents:
BREAKDOWN OF PRIMARY PARTICIPANTS:
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primaries include sales managers, marketing managers, and product managers.
Note 3: Companies are classified into tiers based on their total revenue.
As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=<USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The research methodology used to estimate the size of the Injectable drug delivery market includes the following details.
The market sizing of the market was undertaken from the global side.
Country-level Analysis: The size of the apheresis market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall apheresis market was obtained from secondary data and validated by primary participants to arrive at the total Injectable drug delivery market. Primary participants further validated the numbers.
Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:
Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)
At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall apheresis market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.
Global Injectable Drug Delivery Market Size: Top-Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global Injectable drug delivery market Size: Bottom-Up Approach
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Injectable drug delivery market.
Market Definition:
An injectable drug delivery system refers to a method of administering medication directly into the body via injection. This system typically involves a syringe or other delivery device to transfer the medication from its container into the patient's bloodstream, muscle tissue, or specific site of action. Injectable drug delivery is often used for medications that cannot be taken orally, either because they would be broken down by the digestive system or because they need to be delivered quickly and precisely to achieve the desired therapeutic effect. These systems can include various types of injections such as intravenous (IV), intramuscular (IM), subcutaneous (SC), or intra-articular (IA), depending on the specific requirements of the medication and the patient's condition.
Key Stakeholders
- Injectable drugs and devices manufacturing companies
- Pharmaceutical and injectable drug manufacturing companies
- Healthcare institutions (hospitals and outpatient clinics)
- Distributors and suppliers of injectable drugs and devices
- Research institutes
- Health insurance payers
- Market research and consulting firms
Report Objectives
- To define, describe, segment, and forecast the global Injectable drug delivery market by type, route of administration, facility of use, formulation packaging, application, end user, and region.
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets1 concerning individual growth trends, prospects, and contributions to the overall Injectable drug delivery market.
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the apheresis market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players in the global apheresis market and comprehensively analyze their core competencies2 and market shares.
- To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
- To benchmark players within the apheresis market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
- Geographic Analysis: Further breakdown of the Latin American apheresis into specific countries and, the Middle East, and Africa apheresis into specific countries and further breakdown of the European apheresis into specific countries
Generating Response ...
Growth opportunities and latent adjacency in Injectable Drug Delivery Market